Esperion to Participate in Upcoming BTIG Biotech Conference

Rhea-AI Summary

Esperion (NASDAQ: ESPR) has announced its participation in the upcoming BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion is a company dedicated to discovering, developing, and commercializing innovative medicines for patients with or at risk for cardiovascular and cardiometabolic diseases.

The company focuses on improving outcomes for patients with high cholesterol by breaking through barriers that prevent patients from reaching their goals. Esperion's approach aligns with healthcare providers' trend towards reducing LDL-cholesterol levels as low as possible, as soon as possible.

For more information about Esperion and its work, interested parties can visit esperion.com and esperionscience.com, or follow the company on X (formerly Twitter) at twitter.com/EsperionInc.

ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET.

Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

When is Esperion (ESPR) participating in the BTIG Biotech Conference?

Esperion (ESPR) is participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET.

What is the main focus of Esperion's (ESPR) work?

Esperion (ESPR) focuses on discovering, developing, and commercializing innovative medicines to improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases, particularly those with high cholesterol.

How does Esperion (ESPR) align with current healthcare trends?

Esperion (ESPR) aligns with the current healthcare trend of reducing LDL-cholesterol levels as low as possible, as soon as possible, by providing innovative solutions to help patients reach their cholesterol goals.

Where can investors find more information about Esperion (ESPR)?

Investors can find more information about Esperion (ESPR) on their websites esperion.com and esperionscience.com, or by following the company on X (formerly Twitter) at twitter.com/EsperionInc.